Loading...
01/10 19:06
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call reveals strong financial performance with significant revenue and EPS growth. The company raised its revenue guidance and demonstrated confidence in continued growth, especially with LUPKYNIS. Although there were some uncertainties regarding FDA requests, the overall sentiment remains positive due to the raised guidance and strong financial metrics. The Q&A section reinforced positive trends and growth potential, contributing to a positive stock price prediction.
Total Revenue (Q3 2025) $73.5 million, up 8% from $67.8 million in Q3 2024. Excluding a $10 million milestone payment in 2024, total revenue increased by 27% year-over-year. The increase is attributed to the growth in LUPKYNIS sales.
Net Product Sales of LUPKYNIS (Q3 2025) $70.6 million, up 27% from $55.5 million in Q3 2024. The growth is due to continued momentum following its inclusion in lupus nephritis treatment guidelines.
Net Income (Q3 2025) $31.6 million, up 119% from $14.4 million in Q3 2024. The increase is driven by higher revenue and operational efficiencies.
Diluted Earnings Per Share (Q3 2025) $0.23, up 130% from $0.10 in Q3 2024. The growth reflects increased net income.
Cash Flows from Operating Activities (Q3 2025) $44.5 million, up 162% from $17 million in Q3 2024. The increase is due to improved operational performance and higher revenue.
Total Revenue (9 months ended September 30, 2025) $205.9 million, up 17% from $175.3 million in the same period of 2024. Excluding a $10 million milestone payment in 2024, total revenue increased by 25% year-over-year, driven by LUPKYNIS sales growth.
Net Product Sales of LUPKYNIS (9 months ended September 30, 2025) $197.2 million, up 24% from $158.6 million in the same period of 2024. The increase is attributed to sustained sales momentum.
Net Income (9 months ended September 30, 2025) $76.4 million, up 1,677% from $4.3 million in the same period of 2024. The significant growth is due to higher revenue and operational efficiencies.
Diluted Earnings Per Share (9 months ended September 30, 2025) $0.55, up 1,733% from $0.03 in the same period of 2024. The increase reflects the substantial rise in net income.
Cash Flows from Operating Activities (9 months ended September 30, 2025) $90 million, up 529% from $14.3 million in the same period of 2024. The growth is driven by improved operational performance and higher revenue.
Cash, Cash Equivalents, Restricted Cash, and Investments (as of September 30, 2025) $351.8 million, compared to $315.1 million as of June 30, 2025, and $358.5 million as of December 31, 2024. The change reflects cash flow dynamics and operational activities.
LUPKYNIS sales growth: Sales grew 27% year-over-year in Q3 2025, leading to an increase in 2025 sales guidance to $265-$270 million.
Aritinercept development: Advancing toward clinical studies in two autoimmune diseases by the end of 2025, following positive Phase I results.
LUPKYNIS inclusion in guidelines: Momentum driven by inclusion in the American College of Rheumatology lupus nephritis treatment guidelines.
Revenue growth: Total revenue for Q3 2025 was $73.5 million, up 8% from Q3 2024, excluding a one-time milestone, revenue increased 27%.
Net income growth: Net income for Q3 2025 was $31.6 million, up 119% from Q3 2024.
Cash flow improvement: Cash flows from operating activities were $44.5 million in Q3 2025, up 162% from Q3 2024.
Share repurchase program: Repurchased 12.2 million shares for $98.2 million, reducing diluted shares outstanding from 149.8 million to 138.2 million.
Legal Risks: Aurinia Pharmaceuticals has filed a legal complaint against Dr. George Tidmarsh regarding statements about voclosporin. This ongoing legal matter could pose reputational and financial risks to the company.
Regulatory Risks: The company is engaging with the FDA regarding new analyses of LUPKYNIS clinical studies. Any unfavorable feedback or additional regulatory requirements could delay or impact the product's market performance.
Product Safety and Efficacy Risks: While LUPKYNIS has shown robust efficacy and safety, the presence of antidrug antibodies (ADAs) in aritinercept trials, even though not associated with adverse effects, could raise concerns in future studies or regulatory reviews.
Market Competition: Aritinercept, targeting autoimmune diseases, faces competition from existing treatments like Benlysta. Its success depends on demonstrating superior efficacy and safety.
Strategic Execution Risks: The company plans to initiate clinical studies for aritinercept in two autoimmune diseases by the end of 2025. Delays or challenges in executing these plans could impact strategic objectives.
LUPKYNIS Sales Guidance for 2025: The company has raised its LUPKYNIS sales guidance for 2025 to a range of $265 million to $270 million, reflecting continued momentum and growth.
Total Revenue Guidance for 2025: The company has increased its total revenue guidance for 2025 to a range of $275 million to $280 million, up from the previous range of $260 million to $270 million.
Aritinercept Clinical Development: Aurinia plans to initiate clinical studies of aritinercept in two autoimmune diseases by the end of 2025, with further development details to be disclosed in early 2026.
Share Repurchase: For the 9 months ended September 30, 2025, the company repurchased 12.2 million shares for $98.2 million and diluted shares outstanding were reduced from 149.8 million to 138.2 million.
The earnings call reveals strong financial performance with significant revenue and EPS growth. The company raised its revenue guidance and demonstrated confidence in continued growth, especially with LUPKYNIS. Although there were some uncertainties regarding FDA requests, the overall sentiment remains positive due to the raised guidance and strong financial metrics. The Q&A section reinforced positive trends and growth potential, contributing to a positive stock price prediction.
The earnings call summary highlights strong financial performance, including significant revenue growth, improved margins, and a notable increase in net income. The company also announced a share repurchase program, which is generally viewed favorably by investors. Despite management's reluctance to provide specific guidance on certain R&D projects, the overall sentiment from the earnings call is positive, supported by raised guidance and improved financial health. The Q&A section did not reveal any major concerns that would significantly offset the positive financial results and strategic initiatives.
The earnings call presents a strong financial performance with a 24% revenue increase and a transition to net income, alongside a robust gross margin. The share repurchase program indicates confidence in the stock. Despite potential challenges like supply chain issues and patent litigation, the optimistic guidance and strategic focus on growth drivers are positive. The Q&A highlights management's proactive approach to market dynamics, suggesting stability and potential growth. Given these factors, the stock is likely to see a positive movement, with a potential increase of 2% to 8% over the next two weeks.
The earnings call indicates strong financial performance with a 24% revenue increase and a shift to net income. The share repurchase program also suggests confidence in stock value. Despite potential supply chain challenges and patent litigation, management's optimism on market expansion and operational efficiency is reassuring. The Q&A revealed positive sentiment towards sales guidance and market growth, with minimal impact from tariffs. Overall, the positive financial metrics, share repurchase, and optimistic guidance outweigh potential risks, suggesting a positive stock price movement.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
